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Abstract
Objectives: Previous research has identified that dementia with Lewy bodies (DLB)
has abnormal pareidolic responses which are associated with severity of visual
hallucinations (VH), and the pareidolia test accurately classifies DLB with VH. We
aimed to assess whether these findings would also be evident at the earlier stage of
mild cognitive impairment (MCI) with Lewy bodies (MCI‐LB) in comparison to MCI
due to AD (MCI‐AD) and cognitively healthy comparators.
Methods: One‐hundred and thirty‐seven subjects were assessed prospectively in a
longitudinal study with a mean follow‐up of 1.2 years (max = 3.7): 63 MCI‐LB (22%
with VH) and 40 MCI‐AD according to current research diagnostic criteria, and
34 healthy comparators. The pareidolia test was administered annually as a
repeated measure.
Results: Probable MCI‐LB had an estimated pareidolia rate 1.2–6.7 times higher
than MCI‐AD. Pareidolia rates were not associated with concurrent VH, but had a
weak association with total score on the North East Visual Hallucinations Inventory.
The pareidolia test was not an accurate classifier of either MCI‐LB (Area under
curve (AUC) = 0.61), or VH (AUC = 0.56). There was poor sensitivity when differ-
entiating MCI‐LB from controls (41%) or MCI‐AD (27%), though specificity was
better (91% and 89%, respectively).
Conclusions: Whilst pareidolic responses are specifically more frequent in MCI‐LB
than MCI‐AD, sensitivity of the pareidolia test is poorer than in DLB, with fewer
patients manifesting VH at the earlier MCI stage. However, the high specificity and
ease of use may make it useful in specialist clinics where imaging biomarkers are not
available.
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Key Points
� Pareidolia responses to ambiguous visual stimuli may be a surrogate for visual
hallucinations
� Pareidolias are more common in dementia with Lewy bodies than in Alzheimer's disease
(AD)
� We found an increased rate of pareidolias in mild cognitive impairment (MCI) with Lewy
bodies than in AD or healthy comparators
� Misperceptions in the pareidolia test are reasonably specific to MCI with Lewy bodies, but
these may lack sensitivity at early stages
1 | BACKGROUND
Visual hallucinations (VH) are a feature of several psychiatric,
neurological and ophthalmological disorders.1 In dementia, VHs are
particularly associated with the clinical syndrome of dementia with
Lewy bodies (DLB) with an estimated prevalence of 55%–78%.2
Complex VH, characteristically of well‐formed images of people or
animals, are one of the core clinical features differentiating clinically‐
suspected Lewy body aetiology from the competing diagnosis of
Alzheimer's disease (AD) in both dementia3 and mild cognitive
impairment (MCI).4
VH may be context‐dependent, and therefore difficult to quan-
tify in clinical or research settings; these are often assessed through
clinical interview after self‐report by the patient, or report of this
apparent phenomenon by an informant. This may limit the detection
of VHs in the absence of insight by the patient, or unavailability of an
informant. Comparable visual illusory phenomena (pareidolias, mis-
perceptions of meaningful forms within ambiguous or visually‐noisy
stimuli) which may be elicited on demand in an experimental
setting have therefore been proposed as proxies of VH.
These pareidolic misidentifications have been shown to be more
common in DLB than in AD or healthy controls, and to be positively
correlated with the frequency of VH.5 This research suggested that
human and animal faces and bodies were the most common illusions
in these tasks, supporting a phenomenological link to DLB‐associated
complex VH. A simplified pareidolia test, where participants report
the presence or absence of illusory faces amongst visual noise scenes,
has similarly shown to be reliable in discriminating DLB from AD
(sensitivity of 81% and specificity of 92%). Pareidolia responses were
more common in DLB than AD and healthy controls, were more
common within cases of DLB with clinically‐judged VH, and positively
correlated with neuropsychiatric inventory (NPI) hallucination (of any
sensory modality) scores.6
While the pareidolia test shows apparent utility in discriminating
hallucinations and DLB at the dementia stage, this utility has not yet
been demonstrated in the prodromal stages of cognitive decline of
MCI with Lewy bodies (MCI‐LB) when cognitive impairments have
begun to manifest. While neuropsychiatric symptoms, including VHs,
may be present at this stage, they may be less common than in DLB
while the full clinical syndrome is still emerging.7,8
We therefore aimed to test the rate of pareidolic mis-
identifications in MCI‐LB in contrast to MCI due to AD (MCI‐AD) and
age‐matched healthy control subjects using the noise pareidolia test,
and to consider the utility of this test in detecting clinically‐judged
complex VH and MCI‐LB. Based on the above findings from the de-
mentia literature, our hypotheses to test were: (1) MCI‐LB patients
would produce more pareidolic responses than MCI‐AD or controls;
(2) pareidolic responses would be more common in clinically‐judged
visual hallucinators than non‐hallucinators, and correlate with
severity of hallucinations; (3) the pareidolia test would acceptably




Recruitment for this longitudinal cohort has been described in depth
previously.9 Briefly, participants over 60 years old were recruited
from memory services, neurology and geriatric medical clinics in
North East England. Prospective participants provided informed
consent before undergoing more detailed screening by a research
study medical doctor, and magnetic resonance (MRI) brain imaging.
Those with possible frontotemporal or vascular aetiologies, parkin-
sonism preceding onset of cognitive symptoms by more than one
year, dementia, or absence of objective cognitive impairment at
screening were excluded. Inclusion criteria were age ≥60 years, and
diagnosis of MCI at screening in accordance with NIA‐AA criteria;
concern about, and objective evidence of decline in cognition with
maintained ability to function independently,10 requiring a Clinical
Dementia Rating (CDR) no higher than 0.5.
2.1.2 | Controls
Healthy participants were recruited from families of patients and
local research involvement services and similarly screened as with
patients undergoing medical review, neurological examination, MRI
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brain imaging, and comprehensive neurocognitive assessment. In-
clusion criteria were being age ≥60 years and cognitively healthy,
with no known brain disease and a CDR of 0.
All participants, both patients and controls, were required to be
medically stable on study entry. Local deprivation was calculated for
each participant from the 2019 English Indices of Multiple Depriva-
tion (IMD); IMD scores are divided at country‐wide deciles so that a
rank of one corresponds to living within one of the 10% most
deprived neighbourhoods in England, and a rank of 10 being within
the 10% least deprived neighbourhoods.11
2.2 | Design
Participants were assessed annually in a longitudinal design with
repeated clinical interview with patient and informant (where avail-
able), medical review, and neurocognitive assessment. Differential
clinical diagnoses (as below) were reviewed annually based on clinical
interview, medical review, and imaging findings.
2.3 | Procedure
2.3.1 | Clinical assessment and imaging
Participants underwent a detailed clinical assessment at baseline
including physical and neurological examination, and at annual
follow‐up visits. Informants were also interviewed if available to
provide further information. Interviews included the Geriatric
Depression Scale, Clinician Assessment of Fluctuations, Dementia
Cognitive Fluctuations Scale, Neuropsychiatric Inventory (NPI) for
informants, North‐East Visual Hallucinations Inventory (NEVHI) for
patients, Unified Parkinson's Disease Rating Scale—Part III, and Mayo
Sleep Questionnaire. Instrumental Activities of Daily Living were
rated by the informant (blind to cause, and therefore sensitive to
non‐cognitive causes of dependence), and the CDR was completed by
the clinical assessor based on this interview.
123I‐FP‐CIT SPECT imaging was offered to all participants at
baseline as previously detailed,12 and repeated at one year follow‐up.
Images were visually rated as normal or abnormal by a five‐person
consensus panel of FP‐CIT imaging experts, blind to clinical infor-
mation. 123I‐mIBG cardiac sympathetic innervation imaging (cardiac
mIBG) was also offered to all participants at baseline; delayed images
(taken ∼ 4 h post‐injection with medium energy collimators) were
quantified with a heart:mediastinum ratio cut‐off of <1.86 consid-
ered abnormal based on local data from healthy controls.13
2.4 | Clinical diagnosis and differential classification
A three‐person consensus panel of experienced old age psychiatrists
(AJT, PCD, JPT) independently reviewed clinical research notes
provided from the clinical interview and assessment annually to
confirm the presence of all‐cause MCI according to NIA‐AA criteria10
at baseline.
Each panel member also independently rated the presence or
absence of each of the four core clinical features of DLB (parkin-
sonism, REM sleep behaviour disorder, fluctuating cognition, and
complex VHs) based on research clinical notes and blind to imaging
results. Core clinical features and imaging results were then incor-
porated along with clinical diagnosis to classify patients as MCI‐AD
(MCI, with no core clinical features of DLB, normal FP‐CIT and
mIBG imaging), possible MCI‐LB (MCI with either one core clinical
feature of DLB and normal imaging, or no core clinical features with
abnormal FP‐CIT and/or mIBG imaging), or probable MCI‐LB (MCI
with two or more core clinical features of DLB, or one clinical feature
with one or more imaging abnormalities). These diagnoses were
therefore consistent with current guidelines for classification of MCI‐
LB in research settings.4
Diagnoses and classifications were repeated and updated after
each follow‐up assessment. In the case that participants were seen to
have lost functional independence at follow‐up assessment, all‐cause
criteria for dementia were considered.14 No further follow‐up was
undertaken after diagnosis of dementia.
2.5 | Neurocognitive assessment
A detailed neurocognitive assessment battery was administered to all
participants separately from the clinical review, including the
Addenbrooke's Cognitive Examination—Revised (ACE‐R) as a test of
global cognitive function from which Mini Mental State Examination
(MMSE) was derived, the National Adult Reading Test (NART) was
administered at baseline as an estimator of premorbid function.
Additional assessments were administered, but not considered for
this work, having being detailed elsewhere.8
2.6 | Pareidolia test
The 40‐item visual noise pareidolia test6 was administered at base-
line and repeated at annual follow‐up in the same manner: forty
black‐and‐white visual noise images were presented sequentially on
laminated cards. Individually differing human face images were pre-
sented within the noise in eight of these stimuli, and the remaining 32
contained only visual noise. After being shown three example stimuli
to become acquainted with the task (two with faces, one without),
participants were allowed up to 30 s to view each of the 40 test
pages and asked to report if they did, or did not, see a face in each
image. The test administrator recorded responses, out of view and
without feedback or correction to the participant, as either correct
(correctly identifying a face which was present, or correctly identi-
fying a non‐face stimulus), missed (missing a face which was present),
or a pareidolia (where the participant identified a face as being
present in a noise‐only image). When providing ambiguous responses
(e.g., ‘maybe’), participants were prompted to provide either a ‘yes’ or
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‘no’ answer. As in previous studies, the count of pareidolia responses
was the outcome of interest.
2.7 | Analysis
To assess group differences in the production of pareidolia re-
sponses, incorporating repeat assessments over time to maximise
data availability and account for any time trends (e.g., increased
pareidolia rates as MCI progressed), a generalised linear mixed model
with log link function was estimated using the lme4 package for R
software. Model fit was assessed by the Akaike Information Criterion
(AIC). Subject‐specific random intercept and time slope were
included, as were relevant covariates by block entry, with continuous
variables centred to a meaningful reference value, mean integer or
median to aid in intercept interpretation: time since baseline
assessment (in years), presence of visual impairment reported at
health screening, global cognitive function (ACE‐R score, time‐vary-
ing; centre at 84), premorbid function (NART estimated IQ; centre at
100), gender (female as reference), age (centre at 75 years), educa-
tion (years in education, centre at 13), and local deprivation (IMD
rank, centre at 5). Up to third‐degree polynomials were assessed for
all continuous variables to allow for non‐linear effects. Diagnostic
group (Model 1) and VH presence (time‐varying, where applicable) as
rated by the clinical panel (Model 2) were included as hypothesis‐
testing fixed effects, with group � time interactions included when
supported by improvements in model fit.
Significance was considered as p < 0.05 for hypothesis‐testing
effects, after controlling for relevant covariates.
To assess the sensitivity and specificity of the pareidolia task in
classifying a) clinically‐judged VHs and b) MCI‐LB (possible or
probable), receiver operating characteristic (ROC) curves were
plotted, and the area under the ROC curve (AUC) derived with the
plotROC package for R software. Sensitivity and specificity of this test
in differentiating MCI‐LB were assessed using cut‐offs previously
identified from the dementia stages: ≥ 5 pareidolia errors (vs. MCI‐
AD) or ≥3 errors (vs. controls).6 Classification analyses made use of
baseline test data only, to eliminate the influence of further decline
on pareidolia error rates.
3 | RESULTS
3.1 | Baseline characteristics
One‐hundred and three MCI patients and 34 healthy controls were
available for inclusion (Figure 1). A median of two observations
(baseline and 1‐year follow‐up) were available for each participant
(Mean follow‐up time = 1.2 years, SD = 0.99, max = 3.7 years).
Demographics and baseline task performance are presented in Ta-
ble 1. Consistent with the respective dementia syndromes, there was
a gender disparity between MCI‐AD and MCI‐LB groups, with the
former being predominantly female, and the latter predominantly
male. VH were not as prevalent in MCI‐LB as previously observed in
DLB, being identified in 14 out of 64 cases (22%) at baseline at this
earlier stage.
3.2 | Pareidolia analysis
Second‐degree polynomials (linear and quadratic terms) were sup-
ported for the fixed effect of time only. No interactions with diag-
nosis were supported, and the resulting best‐fitting models are
presented in Table 2, with covariate effects in Table S1. Model 1
assessed diagnostic group differences in rate of producing pareidolia
responses. The expected pareidolia count at the intercept (reference
group: MCI‐AD) was 0.79 (95% CI: 0.38–1.67). Healthy controls did
not significantly differ in their test performance from MCI‐AD, with
expected pareidolia counts of 0.60. Probable MCI‐LB were signifi-
cantly more likely than MCI‐AD to falsely perceive faces within noise
stimuli (1.22 to 6.69 times the rate of pareidolias: expected count of
2.26). While possible MCI‐LB had a similar point estimate to probable
MCI‐LB, there was more uncertainty in this estimate, and so this was
not significantly different from MCI‐AD (0.97 to 7.13 times the rate
of pareidolias: expected count of 2.07). There was a slight positive
growth in pareidolia response rates over time initially, though this
was attenuated by the quadratic term over longer time periods,
which may reflect the exclusion of dementia cases after follow‐up.
These associations remained after controlling for the presence or
absence of clinically‐judged complex VHs at baseline or follow‐up as
a time‐varying predictor (Model 2), which was not a significant pre-
dictor of pareidolic responses. The variance inflation factor for each
component was low (all < 2 across both models), suggesting there
was little collinearity between predictors.
In both models the marginal R2 was relatively low compared to
the conditional R2, suggesting that much of the variance in this
measure could be attributed to individual‐level differences in task
performance. This is supported by the expected pareidolia values
being low, even in MCI‐LB groups, compared to the true observed
range of pareidolia responses produced at baseline (see Table 1).
Repeated‐measure correlations found no significant association
between pareidolia responses and NPI‐measured hallucinations
score as rated by informants (r [71] = 0.03, p = 0.782), but did sup-
port a weak positive correlation between pareidolia production and
total score on the NEVHI as rated by patients (r [120] = 0.22,
p = 0.017).
3.3 | Classification analysis
Despite broad group differences in pareidolia response rates, the
pareidolia test was found to have poor utility in classifying both
hallucinating MCI cases specifically (AUC = 0.56), and MCI‐LB
(AUC = 0.61) in general (see Figure S1). Using cut‐offs identified
from the dementia stage,6 the noise pareidolia test had a sensitivity
of 27% (95% CI: 16%–40%) and specificity of 89% (75%–97%) in
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F I G U R E 1 Recruitment flowchart for healthy controls and mild cognitive impairment (MCI) groups
T A B L E 1 Baseline characteristics and task performance
Control (n = 34) MCI‐AD (n = 40) Possible MCI‐LB (n = 20)
Probable
MCI‐LB (n = 43) p Value
Female gender 10 (29.4%) 23 (57.5%) 9 (45.0%) 7 (16.3%) <0.001a
Age 74.2 (7.45) 76.2 (7.54) 74.1 (7.95) 74.9 (6.36) 0.598b
Years in education 14 [8.5, 24] 11 [10, 20] 11 [9, 25] 11 [9, 21] 0.007c
Local deprivation decile rank 6.5 [1, 10] 6 [1, 10] 3.5 [1, 10] 5 [1, 10] 0.078c
Instrumental activities of daily living ‐ 8 [2, 8] 7 [3, 8] 6 [4, 8] 0.012c
National Adult Reading Test
Estimated Full‐Scale IQ
114 (8.64) 109 (12.3) 102 (11.4) 108 (9.54) <0.001b
Mini Mental State Examination 28.5 (1.13) 26.9 (2.05) 26.0 (2.97) 26.4 (2.47) <0.001b
Addenbrooke's Cognitive
Examination—revised, total
92.7 (4.3) 82.4 (8.3) 78.0 (11.3) 83.0 (9.2) <0.001b
Neuropsychiatric Inventory—Total ‐ 5 [0, 34] 3 [0, 44] 15 [0, 52] 0.011c
Neuropsychiatric Inventory—Hallucinations ‐ 0 [0, 1] 0 [0, 4] 0 [0, 8] 0.006c
North‐East Visual Hallucinations Inventory 0 [0, 3] 0 [0, 7] 1 [0, 15] 0 [0, 16] <0.001c
Pareidolia task—Pareidolias 0 [0, 5] 1 [0, 16] 2 [0, 20] 2 [0, 14] 0.007c
Pareidolia task—Misses 0 [0, 1] 0 [0, 3] 0 [0, 3] 0 [0, 2] 0.371c
Visual hallucinations 0 (0%) 0 (0%) 4 (20.0%) 10 (23.3%) <0.001a
Any visual impairment 2 (5.9%) 3 (7.5%) 2 (10.0%) 2 (4.7%) 0.868a
Note: Mean (SD), Median [Range], or Count (%).




HAMILTON ET AL. - 1411
differentiating MCI‐LB from MCI‐AD (cut‐off ≥ 5 pareidolia re-
sponses), and sensitivity of 41% (28%–55%) and specificity of 91%
(76%–98%) in differentiating MCI‐LB from healthy controls
(cut‐off ≥ 3).
4 | DISCUSSION
4.1 | Summary of aims and findings
We aimed to assess if differences in performance on the noise par-
eidolia test observed between DLB and AD would also be present in
the respective MCI stages of these.
We found only limited support for our hypotheses; probable
MCI‐LB were found to make more pareidolic mispercetions when
completing this test than MCI‐AD and controls, consistent with
previous findings in DLB6 but this association was not clearly found in
the possible MCI‐LB group.
There was no clear association between rates of pareidolic mis-
perceptions and the presence of complex VHs as assessed by an
expert clinical panel, contrary to the hypothesis. No association was
found between pareidolia rates and hallucination severity (of any
sensory modality) assessed by the NPI, but a weak association was
found more specifically with simple and complex VH severity as
measured by the NEVHI.
Finally, the utility of the noise pareidolia test in classifying either
MCI‐LB or clinical VHs was not supported; while the noise pareidolia
test was able to differentiate MCI‐LB from MCI‐AD or healthy
controls with good specificity, cut‐off values from DLB had low
sensitivity when applied to MCI‐LB.
4.2 | Interpretation
These results partially extend previous findings to suggest that dif-
ferences in the experience of pareidolias between DLB and AD5,6
may already be apparent at the MCI stages of these aetiologies, with
a higher rate of pareidolic responses in MCI‐LB, though this was
limited to the most diagnostically clear sub‐group of probable MCI‐
LB. However, there was considerable subject‐level variability in the
reporting of perceived faces not attributable to any considered var-
iable. Consequently, the noise pareidolia test had less predictive
value in classifying either a Lewy body syndrome, or VHs in MCI, in
comparison to the dementia stage.6 However, as a simple assessment
with relatively low time cost and good specificity for MCI‐LB, the
pareidolia test may have value as an accessible early screening test
for suspected MCI‐LB in settings where more accurate but costly
markers such as FP‐CIT or mIBG imaging are not available.
VH were much less common in this MCI‐LB sample than is typical
in DLB (22% vs. 55%–78%),2 and pareidolias also occurred at higher
rates in previous studies than in our own (mean of 3.5 in MCI‐LB vs.
7.3 in DLB)6 which may account for the limited utility of the noise
pareidolia task in classifying these and MCI‐LB. As our MCI patients
were in the prodromal stage it remains likely that their clinical
symptoms will continue to develop with more VH emerging closer to
the onset of, and during, dementia. Pareidolic misidentifications may
T A B L E 2 Generalised linear mixed models estimating pareidolia response production differences between diagnostic groups (Model 1)
and hallucinators (Model 2). Intercept as expected count, fixed effects as incidence rate ratio
Model 1. Model 2.
Fixed effects (reference group/value) Incidence rate ratioa 95% CI p Incidence rate ratio 95% CI p
Intercept (MCI‐AD) 0.79 0.38–1.67 0.542 0.79 0.38–1.67 0.537
Healthy Control (vs. MCI‐AD) 0.76 0.30–1.92 0.557 0.77 0.30–1.96 0.584
Possible MCI‐LB (vs. MCI‐AD) 2.62 0.97–7.13 0.059 2.83 1.02–7.85 0.046
Probable MCI‐LB (vs. MCI‐AD) 2.86 1.22–6.69 0.016 3.05 1.27–7.35 0.013
Time, linear term 1.58 1.01–2.45 0.043 1.55 1.00–2.41 0.051
Time2, quadratic term 0.79 0.69–0.91 0.001 0.80 0.69–0.92 0.002
Visual hallucinations present (vs. Absent) ‐ ‐ ‐ 0.67 0.28–1.58 0.357




Marginal R2/Conditional R2 0.211/0.796 0.208/0.799
Abbreviations: AD, Alzheimer's disease; LB, Lewis bodies; MCI, mild cognitive impairment.
aBaseline expected error rate at intercept, incidence rate ratio for all other effects.
bAddenbrooke's Cognitive Examination—Revised.
cNational Adult Reading Test—Estimated Full‐Scale IQ.
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precede the eventual clinical manifestation of VH as a simple form of
visual illusion comparable to the visual perceptual dysfunctions and
progressive decline commonly observed in DLB15,16 and MCI‐LB,17
which have been shown to predict the eventual onset of VHs in
DLB.18 Future work may consider whether pareidolia rates in non‐
hallucinating MCI predict the eventual emergence of complex VH
by the onset of dementia; the prospective identification of complex
VHs may have value in clinical and research settings due to the
previously‐reported association between this particular clinical
feature of DLB and progressive cognitive decline in MCI.19
Several factors could account for both individual‐ and group
differences in the production of pareidolia responses; previous
research has suggested that an increased reliance upon prior
knowledge in discrimination of ambiguous visual imagery may
mediate the associations between Lewy body disorders and VHs.20
When approaching the pareidolia test with a clearly defined objective
(to discriminate faces from noise) some individuals, and particularly
those with MCI‐LB may therefore place relatively more weighting on
this prior expectation, therefore increasing the rate of mis-
perceptions even in the absence of clinically manifest complex VHs.
The high variability in rates of pareidolias even within MCI‐AD
could suggest that, despite uniformity in instructions, individuals
may still vary in their understanding and approach to the test; some
participants may favour a false positive‐minimising strategy (only
reporting unambiguous perception of faces), while others may favour
a false negative‐minimising strategy (reporting faces in the absence
of a true misperception to avoid missing one). With the diagnostic
effect sizes being relatively small in the MCI stages, individual‐level
factors such as these may contribute to the limited classification
utility in prodromal DLB.
While functional independence was highly variable at baseline in
the MCI group with some particularly low IADL scores, these were
assessed to include all contributions to functional dependence,
including motor impairment (previously found to be correlated with
baseline instrumental activities of daily living (IADL) scores in MCI‐
LB, while cognitive scores were not)17 and social or cultural factors
(e.g., the patient's contributions to housework were limited even
prior to onset of any cognitive impairment). Despite some low IADL
scores, all patients were judged to have MCI at baseline as evidenced
by a CDR <1.
4.3 | Strengths and limitations
These data include a moderately‐sized cohort with detailed clinical
assessment and imaging for aetiological classification. We have made
use of flexible modelling approaches to incorporate repeated mea-
sures to appropriately account for individual‐level effects, and
controlled for several anticipated confounding variables.
However, considerable variability was observed in this sample
which was not explained by fixed effects. While we controlled for
visual impairment reported at medical review, no objective mea-
sures of visual acuity were available, though previous research
found no association between visual acuity and pareidolia rates in
this test.6 As a prospective cohort, it is not yet apparent
which patients will develop VH by the time of onset of dementia,
only those who have already done so (a minority of the MCI‐LB
group); while this clinical symptom was modelled as a time‐
varying predictor, it is not clear at this stage if an increased par-
eidolia rate in MCI may precede or predict the eventual clinical
manifestation of VH.
5 | CONCLUSIONS
Probable MCI‐LB had a higher rate of pareidolia responses in the
visual noise pareidolia task than MCI‐AD, who did not clearly differ
from healthy controls. The relationship between hallucinations and
pareidolia responses was not as clear as in dementia, with compari-
sons limited by low rates of hallucinations in MCI. Due to consider-
able inter‐individual variation in task performance, the noise
pareidolia test did not accurately classify MCI‐LB or VH.
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